We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


PharmaNet Hosts Observational Research Symposium in Zurich

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "PharmaNet Hosts Observational Research Symposium in Zurich"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

During this symposium, PharmaNet and industry experts will discuss the challenges of "real world" observational research, one of the fastest growing areas of clinical research. Actual case studies will be examined to reveal optimal approaches for establishing safety and value in the post-approval environment. Topics will include:

•    Data from Observational Studies: Sufficient Evidence of Economic Value? Ruth McAllister, Consultant Health Economist, Abacus International, and David Schwicker, Managing Director, Phase IV Programs LLC
•    Issues in Observational Research: Operational Implications, Jeff Trotter, Executive Vice President, Phase IV Development, PharmaNet
•    Observational Studies and Patient Registries: Operational Approach, Ron Weishaar, Executive Director, Observational Research, Phase IV Development, PharmaNet
•    Stakeholder Perspectives: EMA / Payors, Andrew Roddam, International Head, Center for Observational Research, Amgen UK
•    Case Studies in Patient Registries, Matthew Gordon, Senior Director, Patient Registries, PharmaNet
•    Technological Change and Implications for Observational Research, Ken Ashman, Executive Director, Phase IV European Operations, PharmaNet

If you would like to attend, please contact Patricia Hall